Sandoz

Biogen Faces Italian Antitrust Probe: What It Means for the Multiple Sclerosis Market

FDA · multiple sclerosis · 10 min

Biogen's Italian subsidiary and its US parent are under investigation by the Italian antitrust authority for alleged abuse of a dominant position in the multiple sclerosis market. This probe, stemming from concerns over drug pricing and market practices, could have significant repercussions for Biogen and the broader MS therapeutic area.